Searchable abstracts of presentations at key conferences in endocrinology

ea0029p315 | Cardiovascular Endocrinology and Lipid Metabolism | ICEECE2012

Effects of long-term treatment of hypogonadal men with testosterone undecanoate on blood pressure, fasting glucose, HbA1c and C-reactive protein

Saad F. , Haider A. , Gooren L.

Introduction: Hypogonadism is associated with metabolic syndrome and all its individual components. This study analysed effects of normalization of serum testosterone in mainly elderly, hypogonadal men.Methods: Prospective registry study of 252 men (mean age 60.6±8.0 years), with testosterone levels between ≤3.5 ng/ml. They received parenteral testosterone undecanoate 1000 mg at day 1, week 6 and every 12 weeks thereafter for up to 66 months.<...

ea0029p1021 | Male Reproduction | ICEECE2012

Side effect profile of long-term treatment of hypogonadal men with testosterone undecanoate

Saad F. , Haider A. , Gooren L.

Introduction: Testosterone therapy for hypogonadal men has been used for decades. However, there are still concerns regarding the safety of this treatment, particularly in elderly men.Methods: Prospective registry study of 252 men (mean age 60.6±8.0 years), with testosterone levels between ≤3.5 ng/ml. They received parenteral testosterone undecanoate 1000 mg at day 1, week 6 and every 12 weeks thereafter for up to 66 months.<p class="abst...

ea0029p1228 | Obesity | ICEECE2012

Reduction of body weight and waist circumference after long-term treatment of hypogonadal men with testosterone undecanoate

Saad F. , Haider A. , Gooren L.

Introduction: Obesity is associated with reduced testosterone, and low testosterone induces weight gain. This study analysed the effects of normalization of serum testosterone in mainly elderly, hypogonadal men.Methods: Prospective registry study of 252 men (mean age 60.6±8.0 years), with testosterone levels between ≤ 3.5 ng/ml. They received parenteral testosterone undecanoate 1000 mg at day 1, week 6 and every 12 weeks thereafter for up to 6...

ea0026p150 | Male reproduction | ECE2011

Testosterone administration to hypogonadal men for a period of up to 42 months improves features of the metabolic syndrome

Saad F , Haider A , Yassin A , Gooren L

Objectives: Elderly men often show a concurrence of a decline of testosterone with features of the metabolic syndrome.Materials and methods: One hundred and twenty-two men of a mean age of 59.5±6.0 years, with baseline testosterone 5.9–12.1 nmol/l were treated with parenteral testosterone undecanoate for 42 months as the sole intervention.Results: Plasma testosterone rose from 9.3±1.7 to 18.7±2.1 nmol/l reaching...

ea0026p151 | Male reproduction | ECE2011

Safety of 42 months of treatment with of long-acting parenteral testosterone undecanoate in men with late-onset hypogonadism

Saad F , Haider A , Yassin A , Gooren L

Objectives: To investigate the safety of the administration of long-acting parenteral testosterone undecanoate (TU) to hypogonadal, mainly elderly men.Design and methods: One hundred and twenty-two men of a mean age of 59.5±6.0 years, with baseline testosterone 5.9–12.1 nmol/l were treated with parenteral TU. These 122 patients were followed for 42 months.Results: Plasma levels of testosterone rose from 9.3±1.7 to 18...

ea0026p335 | Obesity | ECE2011

Long-term effects of normalization of testosterone on variables of the metabolic syndrome in hypogonadal men: the moscow study

Gooren L J , Kalinchenko S Y , Tishova Y A , Mskhalaya G J , Giltay E J , Saad F

Introduction: Men with the metabolic syndrome have low plasma testosterone (T) levels. We aimed to study whether normalization of plasma T in such men improved features of the metabolic syndrome over the longer term.Design/methods: 145 men, 35 to 70 years, with the metabolic syndrome and hypogonadism (baseline total testosterone level <12.0 nmol/l or calculated free T level <225 pmol/l). They had received treatment for 30 weeks with either parent...